Literature DB >> 10977920

Pharmacokinetics of new nootropic acylprolyldipeptide and its penetration across the blood-brain barrier after oral administration.

S S Boiko1, R U Ostrovskaya, V P Zherdev, S A Korotkov, T A Gudasheva, T A Voronina, S B Seredenin.   

Abstract

Pharmacokinetics of GVS-111, a new acylprolyldipeptide with nootropic properties and its penetration across the blood-brain barrier were studied in rats using HPLC. It was found that the dipeptide is absorbed in the gastrointestinal tract, enters the circulation, and penetrates through the blood-brain barrier in an unmodified state.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10977920     DOI： 10.1007/BF02439270

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN： 0007-4888            Impact factor:   0.804


  2 in total

1.  A New Component in the Mechanism of Regulation of Endogenous Depressive-Like States.

Authors:  T L Garibova; T A Gudasheva; S B Seredenin
Journal:  Dokl Biochem Biophys       Date:  2019-11-25       Impact factor: 0.788

2.  Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation.

Authors:  Rita U Ostrovskaya; Yulia V Vakhitova; Uliyana Sh Kuzmina; Milyausha Kh Salimgareeva; Liana F Zainullina; Tatiana A Gudasheva; Vener A Vakhitov; Sergey B Seredenin
Journal:  J Biomed Sci       Date:  2014-08-06       Impact factor: 8.410
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.